

Corporate Presentation

August 24, 2023

Erik Kinnman, M.D., PhD, MBA
CEO



Forward-looking statement

Important notice

The information in this presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would require preparation of further prospectuses or other offer documentation, or be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction.

No representation or warranty expressed or implied is made as to, and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinion contained herein.

The information in this presentation may not be forwarded or distributed to any other person and may not be reproduced in any manner whatsoever. Any forwarding, distribution, reproduction, or disclosure of this information in whole or in part is unauthorized. Failure to comply with this directive may result in a violation of the Securities Act or the applicable laws of other jurisdictions.

Forward looking statements

This presentation contains forward-looking statements that reflect management's current views with respect to certain future events and potential financial performance. Although Vivesto believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. Accordingly, results could differ materially from those set out in the forward-looking statements as a result of various factors.

Important factors that may cause such a difference for Vivesto include but are not limited to: (i) the macroeconomic development, (ii) change in the competitive climate and (iii) change in interest rate level.






This presentation does not imply that Vivesto has undertaken to revise these forward-looking statements, beyond what is required by applicable law or applicable stock exchange regulations if and when circumstances arise that will lead to changes compared to the date when these statements were provided.

Oncology focused R&D company




- Track record of bringing a product to the market and from commercial production
- Focus on developing drugs from preclinical stage to clinical PoC
 - Deliver opportunities in existing portfolio and XR technology platform
 - Expand portfolio
- **Nasdaq Stockholm small cap: [vive.st](https://www.vivesto.se)**
 - MCAP ~120 MSEK
 - Cash 102 MSEK Q2 2023


Our current portfolio

Product	Indication	Pre-clinical	Phase I	Phase II	Phase III	Registration/ approval	Commercial launch	Geography
Apealea (paclitaxel micellar)	Ovarian cancer							EU/EEA
Apealea (paclitaxel micellar)	Ovarian cancer							USA
Cantrixil IP	Ovarian cancer							Global
Docetaxel micellar	Prostate cancer							EU/EEA
Cantrixil	Other forms of cancer							Global

Vivesto animal portfolio

Drug	Specie	Indication	Preclinical	Phase I	Phase I/II PoC	Phase III Pivotal	Markets
Paccal Vet (Paclitaxel Micellar)	Canine (dog)	Metastatic malignant melanoma (MM) Postsplenic hemangiosarcoma (HSA)					US/EU

Portfolio and technology platform activities



Small
molecules


- **Apealea launch**
 - Vivesto seeks to transfer Apealea rights to new licensee
- **Paccal vet**
 - MUMS (Minor Use in a Major Species) designation application
 - Clinical trial initiation planned for H2 2023



Solubilization
technologies
(XR-17™/XR-18)

- **Docetaxel micellar**
 - Study recruitment completed at 11/18 patients
 - Final phase Ib clinical study results 2024
- **Cantrixil**
 - Production clinical trial material
 - Alternative bladder and hematological cancer indications investigated
- **XR-18 drug delivery platform progress**

XR-17™/XR-18 - solubilization technology to improve safety & efficacy



- ✓ High drug delivery capability
- ✓ Shorter infusion time^{1,2}
- ✓ Superior solubility
- ✓ Enhanced API bioavailability
- ✓ Validated safety in cancer¹
- ✗ No or limited need for pre-medication¹
- ✗ No alcohol, Crem. EL, Polys.80, human albumin

Potential cancers

- ✓ Ovarian
- ✓ Prostate
- ✓ Bladder
- ✓ Lung
- ✓ Breast

1) Apealea Summary of Product Characteristics. www.ema.europa.eu



2) Paclitaxel 6 mg/ml Summary of Product Characteristics. <https://products.mhra.gov.uk>

Apealea®



 Vivesto

Apealea® - New licensee/s to be identified



- **Apealea (paclitaxel micellar)**
 - Solvent-free formulation of paclitaxel
 - XR-17 technology platform
- **European market approval**
 - Market launched in Germany by Inceptua
- **New licensee/s**
 - Opportunity to find more suitable partner(s)
 - Regional or global basis

Paccal vet



Paccal vet planned for clinical trial H2 2023

- Low risk + significant value opportunity





- **Paccal Vet = paclitaxel micellar (XR-17™)**
 - Paclitaxel is not available for dogs as they do not tolerate cremophor, nor human albumin
 - XR-17 allows for efficient and safe delivery also in animals
 - Manufacturing process in place since Paccal Vet is identical to Apealea
 - Short time to market
- **Compelling market opportunity**
 - 90 million pet dogs in the US and 93 million in Europe
 - Global companion animal health market 17 BUSD (2021), CAGR of 6%
- **Indication seeking study planned H2 2023**
 - Hemangiosarcoma and Metastatic melanoma (MUMS indications)
 - Positive and supportive interaction with the FDA
- **Partnering opportunity**

Oncology pipeline and XR platform



Cantrixil – new mechanism of action





- Cytotoxic small molecule against CD44+:
 - Can overcome drug resistance¹
 - Lowers cell proliferation²
 - Increases cell death²
 - Impacts mitochondrial metabolic reprogramming^{3,4}
- In clinical development for late-stage ovarian cancer
 - Study drug supply produced
- Opportunity to expand indication area
 - Bladder cancer and blood cancer

¹ McLoughlin et al, *Pharmaceuticals*, 2020, 13, 8. ² Saif et al., *Cancer Chemother. Pharmacol.*, 2017, 79(2), 303.

³ Sica et al., *Int. J. Cancer*, 2020, 146(1), 10. ⁴ Jagust et al., *Front. Pharmacol.*, 2019, 10.

Docetaxel micellar – Phase Ib ongoing

- Docetaxel micellar i.v.
 - Standard of care for advanced prostate cancer, approved for many solid malignancies
 - XR-17™ to enable administration without solubility enhancers
- Open-label trial phase Ib
 - Chemotherapy-naïve patients with metastatic castration-resistant prostate cancer
 - Maximum tolerated dose
- Study recruitment completed at 11/18 patients
 - Cortisone premedication not needed
 - Expected Paclitaxel adverse events
- Final results 2024



Near-term focus & activities

- Cantrixil preclinical data H2 2023
- Paccal Vet Clinical trial initiation H2 2023
- XR-18 platform data H2 2023
- Docetaxel micellar clinical study results 2024
- New licensee Apealea
- Runway extension until end 2024
 - Cost reductions



Thanks

Vivesto AB (STO: VIVE)
Gustav III:s Boulevard 46,
5th floor
169 73 Solna,
Sweden

+46 018-50 54 40

IR@vivesto.com

www.vivesto.com

www.linkedin.com/company/vivesto-ab

www.twitter.com/vivesto



Main shareholders

#	Ägare	Kapital
1	Per Arwidsson med närstående	24,84%
2	Avanza Pension	5,71%
3	Ilija Batljan	1,83%
4	Johan Zetterstedt	1,49%
5	Swedbank Försäkring	1,42%
6	Nordnet Pensionsförsäkring	1,25%
7	Mastan AB (Håkan Lagerberg)	1,15%
8	Jerry Wiström	0,90%
9	Philip Du Rietz	0,86%
10	Christer Ericson	0,72%
11	SEB Fonder	0,58%
12	Jan Lundberg	0,56%
13	Handelsbanken Fonder	0,51%
14	Handelsbanken Liv Försäkring AB	0,50%
15	Håkan Svanberg	0,50%
16	Lars Widell	0,50%
17	Thoren Tillväxt AB	0,45%
18	Skandia Fonder	0,45%
19	Carl Michael Augustsson	0,45%
20	Chirp AB	0,39%
21	Kent Olsson	0,39%
22	Försäkringsaktiebolaget Skandia	0,36%
23	Kéri Annfinnur Hansen	0,35%
24	Lars Ingelson	0,30%
25	FCG Fonder	0,26%